• 3044am永利集团

    Global
    关于3044am永利集团

    致力于纳米抗体
    创新药物研发

    关于3044am永利集团
    科研论文
    截止现在，3044am永利集团生物研发团队在具有重要影响力的期刊上发表研究论文多篇。
    2023-11-06
    TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
    发表于:J Nanobiotechnology. 2023 Nov 6;21(1):410
    查看更多内容
    2023-09-21
    Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis
    发表于:Int J Nanomedicine. 2023 Sep 21;18:5407-5422
    查看更多内容
    2022-11-19
    Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma
    发表于:Respiratory Research. 2022 Nov 19;23(1):316
    查看更多内容
    2022-10-24
    Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein
    发表于:Cells. 2022 Oct 24;11(21):3355
    查看更多内容
    2022-10-03
    Atomically dispersed Mn boosting photoelectrochemical SARS-CoV-2 spike protein immunosensing on carbon nitride
    发表于:Journal of Environmental Chemical Engineering. 2022 Dec;10(6):108697
    查看更多内容
    2022-07-22
    Evaluation of SARS-CoV-2-neutralizing Nanobody Using Virus Receptor Binding Domain Administered Model Mice-Research-2022
    发表于:Research (Wash D C). 2022 Jul 22;2022:9864089
    查看更多内容
    总计 24 1234